NCT05879744View on ClinicalTrials.gov

A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

May 31, 2023

Primary Completion Date

November 30, 2026

Study Completion Date

April 30, 2027

Conditions
NHL, Relapsed, AdultNHL
Interventions
DRUG

CLN-978

CD19xCD3 T cell engager

Trial Locations (6)

30322

Winship Cancer Institute at Emory University, Atlanta

35294

University of Alabama at Birmingham, Birmingham

75390

University of Texas Southwestern Medical Center, Dallas

91010

City of Hope, Duarte

02114

Massachusetts General Hospital, Boston

07601

Hackensack University Medical Center, Hackensack

Sponsors
All Listed Sponsors
lead

Cullinan Therapeutics Inc.

INDUSTRY